Global pioneer in the pharmaceutical cannabis sector with exclusive market access seeks strategic equity partner
Opportunity to invest in fully turnkey, GMP-certified Jamaican pharmaceutical cannabis manufacturer positioned to expand in Brazil & launch in the US once rescheduling takes place. With pharma licensing, export permits & duty-free trade agreements, the company's near-shore facility is poised to lead both pharmaceutical & medical cannabis markets globally
Listing ID:
17608817997
Licence(s) Held:
GMP-certified pharmaceutical manufacturing license, ANVISA Import Permits (Brazil), DEA Import Permits (United States), Licensed for controlled substance manufacturing and export
Seeking US $10M in equity financing at a $20M pre-money valuation to accelerate global market expansion
Listing Details:
Leading Jamaican pharmaceutical cannabis manufacturer, uniquely positioned to capitalize on the rapidly growing US and Brazilian markets by offering the highest level of quality, medical-grade products, and regulatory compliance that surpass traditional medical cannabis offering
Company has an exclusive 5-year supply agreement in Brazil to provide pharmaceutical THC into a state-owned pharma network, serving over 40 million people with 100% insurance reimbursement.
Positioned for direct-to-consumer and direct-to-pharmacy distribution in the US, aligning with the DEA’s expected rescheduling of THC to Schedule III in 2025.
Over 100 pharmaceutical THC shipments have been successfully exported to Brazil and the US under DEA and ANVISA import permits.
Established strategic joint venture in Brazil with a leading distributor grants access to 13,000 pharmacies and 300,000 food and beverage points of sale across all 27 Brazilian states.
EBITDA is forecasted to be positive by Q4 2025, with projected revenues of $10.8M for 2025 and $36.5M by 2026, driven by long-term contracts.
Proven leadership team, consisting of seasoned executives with expertise in pharmaceuticals, consumer goods, and cannabis, including early pioneers of leading cannabis firms.
The GMP-certified facility allows for white-label manufacturing for US brands seeking compliant, pharmaceutical-grade THC for legal distribution across all 50 states post-rescheduling.
Company has invested $10M USD to date, supported by a licensed and GMP-certified pharmaceutical manufacturing facility located in a Free Trade Zone.
The 5-year DCF valuation stands at $138M, representing significant investment upside based on projected sales, market expansion, and regulatory tailwinds.
Seeking US equity financing to scale into the prescription cannabinoids market in the US and Brazil, with additional countries and prescription psychedelics (both psilocybin and ibogaine) as incremental upside.
Pharmaceutical Cannabis Market Growth and Strategic Advantages:
The pharmaceutical cannabis market is rapidly growing, with Brazil’s market expected to reach $14.2B by 2030 (71.4% CAGR) and the US market projected to hit $19.7B by 2030 (65.3% CAGR).
Low-cost jurisdiction, operations in Jamaica's Special Economic Zone provide duty-free export advantages to the US, Brazil, UK, EU, and other global markets. Note: duty-free trade with only 12.5% corporate tax.
US market is seen as a "free call option," with valuation projections excluding potential US revenues, adding upside for investors after the DEA reschedules THC.
17608817997